{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:37:33Z","timestamp":1789576653772,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA168504"],"award-info":[{"award-number":["P50CA168504"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondazione Gianni Bonadonna and Associazione Italiana per la Ricerca contro il Cancro"},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1245\/s10434-025-17185-0","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:12:23Z","timestamp":1742533943000},"page":"3965-3974","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of the American Society of Breast Surgeons\u2019 Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy Rates"],"prefix":"10.1245","volume":"32","author":[{"given":"Anna","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sol","family":"Rosito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Bychkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma Q.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillon","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Stopfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy E.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"8","key":"17185_CR1","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","volume":"4","author":"AW Kurian","year":"2018","unstructured":"Kurian AW, Ward KC, Hamilton AS, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. 2018;4(8):1066\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0644.","journal-title":"JAMA Oncol."},{"issue":"7","key":"17185_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","volume":"1","author":"A Desmond","year":"2015","unstructured":"Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;1(7):943\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2690.","journal-title":"JAMA Oncol."},{"issue":"20","key":"17185_CR3","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","volume":"35","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017;35(20):2232\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.71.6480. (Epub 2017 Apr 12).","journal-title":"J Clin Oncol."},{"issue":"10","key":"17185_CR4","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","volume":"26","author":"ER Manahan","year":"2019","unstructured":"Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic` testing for hereditary breast cancer from the American society of breast surgeons. Ann Surg Oncol. 2019;26(10):3025\u201331. https:\/\/doi.org\/10.1245\/s10434-019-07549-8.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17185_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.hoc.2022.08.003","volume":"37","author":"M Robson","year":"2023","unstructured":"Robson M. Testing for inherited susceptibility to breast cancer. Hematol Oncol Clin North Am. 2023;37(1):17\u201331. https:\/\/doi.org\/10.1016\/j.hoc.2022.08.003.","journal-title":"Hematol Oncol Clin North Am."},{"issue":"9","key":"17185_CR6","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1245\/s10434-021-09855-6","volume":"28","author":"KA Metcalfe","year":"2021","unstructured":"Metcalfe KA, Eisen A, Poll A, et al. Frequency of contralateral prophylactic mastectomy in breast cancer patients with a negative BRCA1 and BRCA2 rapid genetic test result. Ann Surg Oncol. 2021;28(9):4967\u201373. https:\/\/doi.org\/10.1245\/s10434-021-09855-6.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"17185_CR7","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1245\/s10434-020-08889-6","volume":"27","author":"BL Murphy","year":"2020","unstructured":"Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I. Contralateral risk-reducing mastectomy in breast cancer patients who undergo multigene panel testing. Ann Surg Oncol. 2020;27(12):4613\u201321. https:\/\/doi.org\/10.1245\/s10434-020-08889-6.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"17185_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1913948.","journal-title":"N Engl J Med."},{"key":"17185_CR9","volume-title":"An Introduction to Statistical Learning with Applications in R","author":"G James","year":"2017","unstructured":"James G, Witten D, Hastie T, Tibshirani R. An Introduction to Statistical Learning with Applications in R. Springer; 2017."},{"key":"17185_CR10","volume-title":"Statistics for Biology and Health: Logistic Regression, A Self-Learning Text","author":"DG Kleinbaum","year":"2010","unstructured":"Kleinbaum DG, Klein M. Statistics for Biology and Health: Logistic Regression, A Self-Learning Text. Springer; 2010."},{"key":"17185_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-79054-1","volume-title":"Introductory Statistics with R","author":"P Dalgaard","year":"2008","unstructured":"Dalgaard P. Introductory Statistics with R. Springer; 2008."},{"issue":"3","key":"17185_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bimj.201700067","volume":"60","author":"G Heinze","year":"2018","unstructured":"Heinze G, Wallisch C, Dunkler D. Variable selection\u2014a review and recommendations for the practicing statistician. Biometr J Biometrische Zeitschrift. 2018;60(3):431\u201349.","journal-title":"Biometr J Biometrische Zeitschrift."},{"issue":"6","key":"17185_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/jco.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453\u201360. https:\/\/doi.org\/10.1200\/jco.18.01631.","journal-title":"J Clin Oncol."},{"issue":"1","key":"17185_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12885-017-3422-2","volume":"17","author":"EM Grindedal","year":"2017","unstructured":"Grindedal EM, Heramb C, Karsrud I, et al. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer. 2017;17(1):438. https:\/\/doi.org\/10.1186\/s12885-017-3422-2.","journal-title":"BMC Cancer."},{"issue":"3","key":"17185_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/sla.0000000000001698","volume":"265","author":"SM Wong","year":"2017","unstructured":"Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. 2017;265(3):581\u20139. https:\/\/doi.org\/10.1097\/sla.0000000000001698.","journal-title":"Ann Surg."},{"issue":"16","key":"17185_CR16","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1200\/JCO.2010.29.4041","volume":"29","author":"TA King","year":"2011","unstructured":"King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158\u201364. https:\/\/doi.org\/10.1200\/JCO.2010.29.4041.","journal-title":"J Clin Oncol."},{"issue":"6","key":"17185_CR17","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/cam4.1519","volume":"7","author":"N Elsayegh","year":"2018","unstructured":"Elsayegh N, Webster RD, Gutierrez Barrera AM, et al. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 2018;7(6):2718\u201326. https:\/\/doi.org\/10.1002\/cam4.1519.","journal-title":"Cancer Med."},{"issue":"6","key":"17185_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.amjsurg.2021.03.060","volume":"221","author":"AK Bagwell","year":"2021","unstructured":"Bagwell AK, Sutton TL, Gardiner S, Johnson N. Outcomes of large panel genetic evaluation of breast cancer patients in a community-based cancer institute. Am J Surg. 2021;221(6):1159\u201363. https:\/\/doi.org\/10.1016\/j.amjsurg.2021.03.060.","journal-title":"Am J Surg."},{"issue":"4","key":"17185_CR19","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1200\/op.21.00322","volume":"18","author":"V Ro","year":"2022","unstructured":"Ro V, McGuinness JE, Guo B, et al. Association between genetic testing for hereditary breast cancer and contralateral prophylactic mastectomy among multiethnic women diagnosed with early-stage breast cancer. JCO Oncol Pract. 2022;18(4):e472\u201383. https:\/\/doi.org\/10.1200\/op.21.00322.","journal-title":"JCO Oncol Pract."},{"issue":"23","key":"17185_CR20","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316. https:\/\/doi.org\/10.1001\/jama.2017.7112.","journal-title":"JAMA."},{"issue":"9","key":"17185_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","volume":"13","author":"N Tung","year":"2016","unstructured":"Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Review Nat Rev Clin Oncol. 2016;13(9):581\u20138. https:\/\/doi.org\/10.1038\/nrclinonc.2016.90.","journal-title":"Review Nat Rev Clin Oncol."},{"issue":"12","key":"17185_CR22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamasurg.2018.2493","volume":"153","author":"A Weiss","year":"2018","unstructured":"Weiss A, Garber JE, King T. Breast cancer surgical risk reduction for patients with inherited mutations in moderate penetrance genes. JAMA Surg. 2018;153(12):1145\u20136. https:\/\/doi.org\/10.1001\/jamasurg.2018.2493.","journal-title":"JAMA Surg."},{"issue":"7","key":"17185_CR23","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.3390\/cancers14071636","volume":"14","author":"M Sarki","year":"2022","unstructured":"Sarki M, Ming C, Aissaoui S, et al. Intention to inform relatives, rates of cascade testing, and preference for patient-mediated communication in families concerned with hereditary breast and ovarian cancer and lynch syndrome: the Swiss CASCADE cohort. Cancers. 2022;14(7):1636. https:\/\/doi.org\/10.3390\/cancers14071636.","journal-title":"Cancers."},{"issue":"2","key":"17185_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/jgc4.1511","volume":"31","author":"J Wynn","year":"2022","unstructured":"Wynn J, Milo Rasouly H, Vasquez-Loarte T, et al. Do research participants share genomic screening results with family members? J Genet Couns. 2022;31(2):447\u201358. https:\/\/doi.org\/10.1002\/jgc4.1511.","journal-title":"J Genet Couns."},{"key":"17185_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.867226","volume":"13","author":"TJ Schmidlen","year":"2022","unstructured":"Schmidlen TJ, Bristow SL, Hatchell KE, Esplin ED, Nussbaum RL, Haverfield EV. The impact of proband indication for genetic testing on the uptake of cascade testing among relatives. Front Genet. 2022;13:867226. https:\/\/doi.org\/10.3389\/fgene.2022.867226.","journal-title":"Front Genet."},{"issue":"6","key":"17185_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.7326\/0003-4819-159-6-201309170-00003","volume":"159","author":"SM Rosenberg","year":"2013","unstructured":"Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013;159(6):373\u201381. https:\/\/doi.org\/10.7326\/0003-4819-159-6-201309170-00003.","journal-title":"Ann Intern Med."},{"issue":"1","key":"17185_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1245\/s10434-017-6217-4","volume":"25","author":"O Kantor","year":"2018","unstructured":"Kantor O, Ajmani G, Wang CH, Datta A, Yao K. The shifting paradigm for breast cancer surgery in patients undergoing neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(1):164\u201372. https:\/\/doi.org\/10.1245\/s10434-017-6217-4.","journal-title":"Ann Surg Oncol."},{"key":"17185_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1146\/annurev-genom-083118-015253","volume":"21","author":"R Manchanda","year":"2020","unstructured":"Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E. Population screening for inherited predisposition to breast and ovarian cancer. Annu Rev Genomics Hum Genet. 2020;21:373\u2013412. https:\/\/doi.org\/10.1146\/annurev-genom-083118-015253.","journal-title":"Annu Rev Genomics Hum Genet."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17185-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17185-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17185-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:14:46Z","timestamp":1746288886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17185-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["17185"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17185-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anna Weiss reports an institutional research agreement with Myriad Laboratories Inc. Danielle Braun co-leads the BayesMendel Laboratory, which develops and maintains the BayesMendel and PanelPRO software package. This includes a variety of risk assessment tools, including BRCAPRO, PancPRO, MelaPRO, MMRpro, and PanelPRO, which are licensed for commercial use. Filipa Lynce reports consulting roles at Pfizer, AstraZeneca, Daiichi Sankyo, and Eli Lilly, and institutional research support from Gilead, IDEAYA, AstraZeneca, Merck, Zentalis, Pfizer, Eisai, and Incyte. Maria Sol Rosito is supported by Myriad Genetics, Friends of Dana Farber Cancer Institute internal award, and the Susan F. Smith award. Stefania Morganti reports expense reimbursement from Menarini\/Stemline and AstraZeneca. Tari A. King reports speaker honoraria for Exact Sciences and compensated service on the FES Steering Committee, GE Healthcare, as well as compensated service as faculty for the PrecisCa Cancer Information Service. Brenna Barton, Monica McGrath, Sam Stokes, Alison Laws, Laura Warren, Brittany Bychkovsky, Huma Q. Rana, Dillon Davis, Jill Stopfer, and Judy E. Garber have no conflicts of interest to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"DISCLOSURES"}}]}}